冬凌甲草素在体外促进成骨分化和抑制破骨形成及其机制研究

doi:10.3877/cma.j.issn.2095-9605.2020.02.005

目的

研究冬凌甲草素对成骨细胞分化和破骨细胞形成的作用及分子机制。

方法

从SD大鼠股骨和胫骨中分离出骨髓间充质干细胞和骨髓单核细胞，培养于含10%胎牛血清的α-MEM培养基，细胞80%~90%汇合后采用不同浓度的冬凌甲草素（0、1、2、3、4 μM）进行分组干预，CCK-8法及活死染色检测不同浓度的冬凌甲草素对间充质干细胞及骨髓单核细胞活力的影响；通过碱性磷酸酶（ALP）染色、茜素红染色、ALP活性的测定以及TRAP染色检测冬凌甲草素对成骨和破骨分化的影响；qRT-PCR检测wnt1、β-catenin、Runx2、ALP、collage-1(col-1)、骨钙蛋白(OCN)、TRAP、c-Fos、NFATc1和CTSK的表达；Western-blot及免疫荧光检测wnt1、β-catenin、ALP、col-1、OCN、Runx2、核因子κB受体活化因子配体（RANKL）、骨保护素（OPG）、GSK-3β、p-GSK-3β的表达。

结果

（1）与对照组比较，冬凌甲草素（2 μM）具有促进间充质干细胞向成骨细胞分化和提高ALP活性的作用；（2）冬凌甲草素可以促进wnt1、β-catenin、Runx2的表达，在加入Wnt/β-catenin/TCF通路选择性拮抗剂ICG-001后，成骨相关标志物表达下降。（3）冬凌甲草素可以促进OPG而抑制RANKL的表达。（4）冬凌甲草素可以直接或间接抑制破骨相关基因TRAP，NFATc1和c-Fos的表达。

结论

冬凌甲草素可能通过Wnt/β-catenin信号通路促进骨髓间充质干向成骨细胞分化，同时，它还可能抑制RANKL介导的破骨细胞的形成。

关键词: 冬凌甲草素, 间充质干细胞, 骨质疏松症, Wnt, β-连环蛋白, 核因子κB受体活化因子配体, 骨保护素

Objective

To study the effect and molecular mechanism of oridonin on osteoblast differentiation and osteoclast formation.

Methods

BMSCs were isolated from the femur and tibia of SD rats and cultured in α-MEM containing 10% fetal bovine serum; after 80%~90% of the cells confluent, cells were treated with oridonin in different concentrations. CCK-8 and live/dead staining were used to detect the viability of BMSCs and BMMs. ALP straining, alizarin red S staining, ALP activity and TRAP staining were used to detect the effects on osteogenesis and osteoclast differentiation. Related gene expressions (wnt1、β-catenin、Runx2、ALP、col-1、OCN、TRAP、c-Fos、NFATc1 and CTSX) were analyzed by qRT-PCR. Related protein expressions (wnt1、β-catenin、ALP、col-1、OCN、Runx2、RANKL、OPG、GSK-3β、p-GSK-3β) were measured by Western-blot and immunofluorescence.

Results

(1) Compared with the control group, oridonin (0-2 μM) can promote ALP activity and stimulate the differentiation of BMSCs into osteoblasts. (2) Oridonin can stimulate the expression of wnt1, β-catenin, Runx2. The expressions of osteogenic differentiation gene decreased following with adding Wnt/β-catenin/TCF selective antagonist ICG-001. (3) Oridonin can promote the expression of OPG and inhibit expression of RANKL. (4) Oridonin can directly/indirectly inhibit the expression of osteoclast-related genes TRAP, NFATc1 and c-Fos.

Conclusions

Oridonin may promote BMSCs differentiate into osteoblasts through the Wnt/β-catenin signaling pathway. At the same time, it may also inhibit the formation of osteoclasts mediated by nuclear factor-κB receptor activator (NF-κB) ligand (RANKL).

Key words: Oridonin, Mesenchymal stem cells, Osteoporosis, Wnt, β-cantenin, Receptor Activator of Nuclear Factor-κB Ligand, Osteoprotegerin

表1 qRT-PCR引物

基因	序列	?
Runx2	forward	5’-GTTCCCAGGCATTTCATCCC-3’
Runx2	reverse	5’-AAGGTGGCTGGATAGTGCAT-3
ALP	forward	5′-CAAGGATGCTGGGAAGTCCG-3’
ALP	reverse	5′-CTCTGGGCGCATCTCATTGT-3’
Col-I	forward	5′-TAA AGGGTCATCGTGGCTTC-3’
Col-I	reverse	5′-ACTCTCCGCTCT TCCAGTCA-3’
OCN	forward	5’-CTTGAAGACCGCCTACAAAC-3’
OCN	reverse	5’-GCTGCTGTGACATCCATAC-3’;
CTSK	forward	5’-TAATGTGAACCATGCCGTGT-3’;
CTSK	reverse	5’-CGAGCCAAGAGAACATAGCC-3’;
TRAP	forward	5’-TCCTGGCTCAAAAAGCAGTT-3’;
TRAP	reverse	5’-ACATAGCCACACCGTTCTC-3’;
c-Fos	forward	5’-CCAGTCAAGAGCATCAGCAA-3’;
c-Fos	reverse	5’-AAGTAGTGCAGCCCGGAGTA-3’;
NFATc1	forward	5’-GGGTCAGTGTGACCGAAGAT-3’;
NFATc1	reverse	5’-GGAAGTCAGAAGTGGGTGGA-3’;
GAPDH	forward	5’-ACCCAGAAGACTGTGGATGG-3’;
GAPDH	reverse	5’-CACATTGGGGGTAGGAACAC-3’;

表1 qRT-PCR引物

基因	序列	?
Runx2	forward	5’-GTTCCCAGGCATTTCATCCC-3’
Runx2	reverse	5’-AAGGTGGCTGGATAGTGCAT-3
ALP	forward	5′-CAAGGATGCTGGGAAGTCCG-3’
ALP	reverse	5′-CTCTGGGCGCATCTCATTGT-3’
Col-I	forward	5′-TAA AGGGTCATCGTGGCTTC-3’
Col-I	reverse	5′-ACTCTCCGCTCT TCCAGTCA-3’
OCN	forward	5’-CTTGAAGACCGCCTACAAAC-3’
OCN	reverse	5’-GCTGCTGTGACATCCATAC-3’;
CTSK	forward	5’-TAATGTGAACCATGCCGTGT-3’;
CTSK	reverse	5’-CGAGCCAAGAGAACATAGCC-3’;
TRAP	forward	5’-TCCTGGCTCAAAAAGCAGTT-3’;
TRAP	reverse	5’-ACATAGCCACACCGTTCTC-3’;
c-Fos	forward	5’-CCAGTCAAGAGCATCAGCAA-3’;
c-Fos	reverse	5’-AAGTAGTGCAGCCCGGAGTA-3’;
NFATc1	forward	5’-GGGTCAGTGTGACCGAAGAT-3’;
NFATc1	reverse	5’-GGAAGTCAGAAGTGGGTGGA-3’;
GAPDH	forward	5’-ACCCAGAAGACTGTGGATGG-3’;
GAPDH	reverse	5’-CACATTGGGGGTAGGAACAC-3’;

图1 高浓度的ORI抑制骨髓间充质干细胞的增殖。在测量细胞活力之前，用ORI干预原代骨髓间充质干细胞。CCK-8分析（1B）和活/死染色（1C）表明，在浓度大于2 μM的ORI处理72 h后，死亡的BMSC数量显着减少。细胞毒性（活/死）测定图像显示活细胞（绿色）和死细胞（红色）。

图2 ORI对BMSCs成骨分化的影响。以高糖培养基（HSM）作为对照组，成骨培养基（OM）和ORI培养骨髓间充质干细胞。7 d后使用碱性磷酸酶染色法进行测定。2B：在用HSM，OM和ORI培养7天的BMSC上测试了ALP活性。^*P<0.05和^**P<0.01 vs.对照组（n=3）。2C、2D：将骨髓间充质干细胞与HSM（对照）一起，在有或没有ORI的情况下培养14 d。通过茜素红S染色定量。^*P<0.05和#P<0.01 vs.对照组（n=3）。2E、2F、2G：在第2 d收获用OM（对照），ORI（0.5μM、1μM、2μM）培养的骨髓间充质干细胞。通过qRT-PCR评估ALP、col-1和OCN的mRNA表达水平并定量。^*P<0.05和^#P<0.01 vs.对照组。

图3 ORI通过Wnt/β-catenin信号通路促进骨髓间充质干细胞的成骨分化。3A：在第3 d收集分别用OM（对照），ORI（0.5μM、1μM、2μM）培养的骨髓间充质干细胞。通过Westernblot评估Wnt1、β-catenin、GSK-3β和p-GSK-3β的蛋白表达水平。^*P<0.05和^#P<0.01 vs.对照组。3B：测定Wnt1和β-连环蛋白的蛋白质表达水平。^*P<0.05和^#P<0.01 vs.对照组。3C：在48 h收集含OM（对照），有或没有ORI（2 μM）或ICG-001的骨髓间充质干细胞，测定ALP，col-1和OCN的蛋白表达。^*P<0.05和^#P<0.01 vs.对照组。3D：在48 h收集经OM培养的骨髓间充质干细胞（对照）、有或没有ORI或ICG-001组，测定ALP染色和茜素红染色。3E：在48 h收集用OM（对照），有或没有ORI培养的骨髓间充质干细胞。通过qRT-PCR评估并定量β-catenin和Runx2的mRNA表达水平。^*P<0.05和^#P<0.01 vs.对照组。3F：免疫荧光检测β-catenin蛋白的易位。用OM（对照）和ORI（2μM）干预骨髓间充质干细胞。β-catenin在细胞质和细胞核中均表达，并且荧光密度和强度在第5 d呈剂量依赖性增加。细胞核用DAPI染色并显示为蓝色荧光。比例尺=100 μM。3G、3H：在48 h收集用OM（对照），ORI处理的骨髓间充质干细胞。Westernblot评估RANKL和OPG的蛋白表达水平，^*P<0.05和^#P<0.01 vs.对照组。

图4 ORI直接抑制骨髓单核细胞的增殖和分化。4A、4B：ORI在48 h或96 h对骨髓单核细胞生存能力的影响。4C：活/死染色。4D、4E、4H：用M-CSF和RANKL以及不同浓度的ORI干预5 d产生的的TRAP阳性骨髓单核细胞。TRAP阳性多核细胞的定量和破骨细胞面积。^*P<0.05和^#P<0.01 vs.对照组。4F、4G：用ORI处理5 d的骨髓单核细胞中的NFATc1，c-Fos和TRAP表达并定量。^*P<0.05和^#P<0.01 vs.对照组。4I：ORI干预12 h、24 h或48 h的骨髓单核细胞中NFATc1和c-Fos表达水平。^*P<0.05和^#P<0.01 vs.对照组。

图5 ORI间接抑制骨髓单核细胞的分化。5A：用不同浓度的上清液干预5 d的骨髓单核细胞中NFATc1，c-Fos和TRAP的表达并定量。^*P<0.05和^#P<0.01 vs.对照组。5B、5C、5D：TRAP阳性骨髓单核细胞用不同浓度的上清液干预，然后用M-CSF和RANKL孵育5 d。定量TRAP阳性多核细胞和破骨细胞面积。

[1]	Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass[J]. Nature, 2003, 423(6937): 349-355.
[2]	Hadjidakis DJ, Androulakis, II. Bone remodeling[J]. Ann N Y Acad Sci, 2006, 1092:385-396.
[3]	Zaidi M. Skeletal remodeling in health and disease[J]. Nat Med, 2007, 13(7): 791-801.
[4]	Khosla S, Westendorf JJ, Oursler MJ. Building bone to reverse osteoporosis and repair fractures[J]. J Clin Invest, 2008, 118(2): 421-428.
[5]	Zhong Z, Zylstra-Diegel CR, Schumacher CA, et al. Wntless functions in mature osteoblasts to regulate bone mass[J]. Proc Natl Acad Sci USA, 2012, 109(33): E2197-2204.
[6]	Clevers H, Nusse R. Wnt/β-Catenin Signaling and Disease[J]. Cell, 2012, 149(6):1192-1205.
[7]	Lin C, Jiang X, Dai Z, et al. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling[J]. J Bone Miner Res, 2009, 24(10): 1651-1661.
[8]	MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases[J]. Dev Cell, 2009, 17(1): 9-26.
[9]	Kramer I, Halleux C, Keller H, et al. Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis[J]. Mol Cell Biol, 2010, 30(12): 3071-3085.
[10]	Xie Z, Yu H, Sun X, et al. A Novel Diterpenoid Suppresses Osteoclastogenesis and Promotes Osteogenesis by Inhibiting Ifrd1-Mediated and IkappaBalpha-Mediated p65 Nuclear Translocation[J]. J Bone Miner Res, 2018, 33(4): 667-678.
[11]	Liu Y, Liu YZ, Zhang RX, et al. Oridonin inhibits the proliferation of human osteosarcoma cells by suppressing Wnt/beta-catenin signaling[J]. Int J Oncol, 2014, 45(2): 795-803.
[12]	Keating SE, Maloney GM, Moran EM, et al. IRAK-2 participates in multiple toll-like receptor signaling pathways to NFkappaB via activation of TRAF6 ubiquitination[J]. J Biol Chem, 2007, 282(46): 33435-33443.
[13]	Yasui T, Kadono Y, Nakamura M, et al. Regulation of RANKL-induced osteoclastogenesis by TGF-beta through molecular interaction between Smad3 and Traf6[J]. J Bone Miner Res, 2011, 26(7): 1447-1456.
[14]	Hsieh TC, Wijeratne EK, Liang JY, et al. Differential control of growth, cell cycle progression, and expression of NF-kappaB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin, diterpenoids from the chinese herb Rabdosia rubescens[J]. Biochem Biophys Res Commun, 2005, 337(1):224-231.
[15]	Liu Y, Liu YZ, Zhang RX, et al. Oridonin inhibits the proliferation of human osteosarcoma cells by suppressing Wnt/β-catenin signaling[J]. Int J. Oncol. 2014, 45(2): 795-803.
[16]	Xie Z, Yu HJ, Sun XW, et al. A Novel Diterpenoid Suppresses Osteoclastogenesis and Promotes Osteogenesis by Inhibiting Ifrd1-Mediated and IkBa-Mediated p65 Nuclear Translocation[J]. J.Bone Miner. Res, 2018, 33(4): 667-678
[17]	Chen S, Jin G, Huang KM, et al. Lycorine suppresses RANKL-induced osteoclastogenesis in vitro and prevents ovariectomy-induced osteoporosis and titanium particle-induced osteolysis in vivo[J]. Sci Rep, 2015, 5: 12853.
[18]	Lee K, Majumdar MK, Buyaner D, et al. Human mesenchymal stem cells maintain transgene expression during expansion and differentiation[J]. Mol Ther, 2001, 3(6): 857-866.
[19]	Van Damme A, Vanden Driessche T, Collen D, et al. Bone marrow stromal cells as targets for gene therapy[J]. Current gene therapy, 2002, 2(2): 195-209.
[20]	Rantlha M, Sagar T, Kruger MC, et al. Ellagic acid inhibits RANKL-induced osteoclast differentiation by suppressing the p38 MAP kinase pathway[J]. Arch Pharm Res, 2017, 40(1): 79-87.
[21]	Abelson PH. Medicine from plants[J]. Science (New York, NY), 1990, 247(4942): 513.
[22]	Liu YQ, Mu ZQ, You S, et al. Fas/FasL signaling allows extracelluar-signal regulated kinase to regulate cytochrome c release in oridonin-induced apoptotic U937 cells[J]. Biological & pharmaceutical bulletin, 2006, 29(9): 1873-1879.
[23]	Hu HZ, Yang YB, Xu XD, et al. Oridonin induces apoptosis via PI3K/Akt pathway in cervical carcinoma HeLa cell line[J]. Acta Pharmacol Sin, 2007, 28(11): 1819-1826.
[24]	Cheng Y, Qiu F, Ye YC, et al. Oridonin induces G2/M arrest and apoptosis via activating ERK-p53 apoptotic pathway and inhibiting PTK-Ras-Raf-JNK survival pathway in murine fibrosarcoma L929 cells[J]. Arch Biochem Biophys, 2009, 490(1): 70-75.
[25]	Gao FH, Hu XH, Li W, et al. Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-myc[J]. BMC Cancer, 2010, 10: 610.
[26]	Kim JY, Cheon YH, Kwak SC, et al. Emodin regulates bone remodeling by inhibiting osteoclastogenesis and stimulating osteoblast formation[J]. J Bone Miner Res, 2014, 29(7): 1541-1553.
[27]	Du L, Nong MN, Zhao JM, et al. Polygonatum sibiricum polysaccharide inhibits osteoporosis by promoting osteoblast formation and blocking osteoclastogenesis through Wnt/beta-catenin signalling pathway[J]. Sci Rep, 2016, 6: 32261.
[28]	Boudin E, Fijalkowski I, Piters E, et al. The role of extracellular modulators of canonical Wnt signaling in bone metabolism and diseases[J]. Semin Arthritis Rheum, 2013, 43(2): 220-240.
[29]	Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments[J]. Nat Med, 2013, 19(2): 179-192.
[30]	Kimelman D, Xu W. Beta-catenin destruction complex: insights and questions from a structural perspective[J]. Oncogene, 2006, 25(57): 7482-7491.
[31]	Emami KH, Nguyen C, Ma H, et al. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription[J]. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101(34): 12682-12687.
[32]	Wei W, Zeve D, Suh JM, et al. Biphasic and dosage-dependent regulation of osteoclastogenesis by beta-catenin[J]. Mol Cell Biol, 2011, 31(23): 4706-4719.
[33]	Bandara N, Gurusinghe S, Lim SY, et al. Molecular control of nitric oxide synthesis through eNOS and caveolin-1 interaction regulates osteogenic differentiation of adipose-derived stem cells by modulation of Wnt/beta-catenin signaling[J]. Stem Cell Res Ther, 2016, 7(1): 182.

[1]	曹胜军, 李全, 符雪, 邵天喜, 周延华. 人脂肪间充质干细胞多层膜片对促进裸鼠皮肤缺损愈合的效果观察[J]. 中华损伤与修复杂志(电子版), 2024, 19(04): 341-347.
[2]	陈俊秋, 邬绿莹, 马予洁, 林娜, 刘飞, 陈津. 基于lncRNA微阵列芯片技术探索间充质干细胞外泌体增强小鼠胰岛β细胞抗低氧损伤的潜在机制[J]. 中华细胞与干细胞杂志(电子版), 2024, 14(03): 129-136.
[3]	杨阳, 王琤, 周文土, 周冰. Caveolae/Caveolin-1与膜胆固醇共同调控小鼠BMSCs成骨分化[J]. 中华细胞与干细胞杂志(电子版), 2024, 14(03): 137-142.
[4]	李博, 马秀岩, 孙杰. lncRNA TINCR对滋养层HTR-8/SVneo细胞生物学行为的影响及其机制[J]. 中华细胞与干细胞杂志(电子版), 2024, 14(03): 167-172.
[5]	孙海燕, 周士燕, 张杉杉, 张研, 张茜. 间充质干细胞及其外泌体在高原肺水肿中的潜在治疗机制研究进展[J]. 中华细胞与干细胞杂志(电子版), 2024, 14(03): 186-190.
[6]	凌淑洵, 涂玥, 刘思逸. 间充质干细胞在慢性肾脏病研究领域现状和趋势的知识图谱可视化分析[J]. 中华细胞与干细胞杂志(电子版), 2024, 14(02): 73-82.
[7]	王娟, 刘晔, 熊威, 蒋财磊, 贺燕, 叶青松. 间充质干细胞缓解阿尔茨海默病氧化应激的新思路[J]. 中华细胞与干细胞杂志(电子版), 2024, 14(02): 93-106.
[8]	梁国豪, 张茜, 张研. 间充质干细胞及其衍生物治疗高原低氧环境下心血管疾病的研究进展[J]. 中华细胞与干细胞杂志(电子版), 2024, 14(02): 107-112.
[9]	景水力, 王娟, 刘晔, 周亨, 熊威, 叶青松. 间充质干细胞在脊髓损伤中的应用及研究进展[J]. 中华细胞与干细胞杂志(电子版), 2024, 14(02): 113-121.
[10]	陆雅斐, 皇甫少华, 马传学, 江滨. 间充质干细胞治疗肛瘘手术方式的研究进展[J]. 中华结直肠疾病电子杂志, 2024, 13(03): 242-249.
[11]	史敬萱, 焦圆圆, 田景玮, 卓莉. 间充质干细胞来源外泌体治疗动物糖尿病肾脏病的效果：Meta分析[J]. 中华肾病研究电子杂志, 2024, 13(02): 79-86.
[12]	付章宁, 耿晓东, 张永军, 陆宇平, 孙冠南, 张益帆, 蔡广研, 陈香美, 洪权. 间充质干细胞促进肾脏损伤修复机制研究进展[J]. 中华肾病研究电子杂志, 2024, 13(02): 87-91.
[13]	肖伍豪, 刘抗寒. 晚期慢性肾脏病患者骨质疏松症的治疗研究进展[J]. 中华肾病研究电子杂志, 2024, 13(02): 92-96.
[14]	麦麦提依明·托合提, 柳叶, 张诚, 阿卜杜喀迪尔·牙森, 高峰, 王继超, 吴永刚. PEA3和EPHA2在脑胶质母细胞瘤中的表达及在Wnt/β-catenin通路的作用[J]. 中华脑科疾病与康复杂志(电子版), 2024, 14(02): 73-79.
[15]	孙琳, 韩萍萍, 张碧琳, 张军霞. 血清WISP1水平与2型糖尿病患者血尿酸升高的相关性[J]. 中华临床医师杂志(电子版), 2024, 18(02): 178-182.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Oridonin promotes osteogenesis and suppresses osteoclastogenesis in vitro.

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Oridonin promotes osteogenesis and suppresses osteoclastogenesis in vitro.